Medios AG (ILM1.F)
- Previous Close
12.10 - Open
12.00 - Bid 11.94 x --
- Ask 12.08 x --
- Day's Range
12.00 - 12.00 - 52 Week Range
10.32 - 18.52 - Volume
715 - Avg. Volume
463 - Market Cap (intraday)
315.992M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
23.53 - EPS (TTM)
0.51 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.50
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. Medios AG was founded in 2016 and is headquartered in Berlin, Germany.
www.medios.ag472
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ILM1.F
View MorePerformance Overview: ILM1.F
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILM1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILM1.F
View MoreValuation Measures
Market Cap
308.62M
Enterprise Value
440.99M
Trailing P/E
23.73
Forward P/E
7.81
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.16
Price/Book (mrq)
0.60
Enterprise Value/Revenue
0.23
Enterprise Value/EBITDA
6.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.67%
Return on Assets (ttm)
2.81%
Return on Equity (ttm)
2.56%
Revenue (ttm)
1.88B
Net Income Avi to Common (ttm)
12.55M
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
106M
Total Debt/Equity (mrq)
46.94%
Levered Free Cash Flow (ttm)
59.02M